UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 736,866 shares of the company’s stock after selling 139,006 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.89% of Kymera Therapeutics worth $84,496,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of KYMR. GAMMA Investing LLC grew its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the period. US Bancorp DE raised its position in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares during the period. Glenmede Trust Co. NA lifted its holdings in Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares in the last quarter. Cetera Investment Advisers lifted its holdings in Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after purchasing an additional 252 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares during the period.

Kymera Therapeutics Trading Down 0.4%

NASDAQ KYMR opened at $118.63 on Thursday. The stock has a market cap of $9.86 billion, a PE ratio of -36.61 and a beta of 1.96. Kymera Therapeutics, Inc. has a twelve month low of $40.10 and a twelve month high of $130.05. The stock has a fifty day simple moving average of $113.96 and a 200-day simple moving average of $94.49.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. During the same period in the previous year, the firm earned ($0.95) EPS. Kymera Therapeutics’s revenue was up 465.2% on a year-over-year basis. Research analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KYMR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Morgan Stanley reiterated an “overweight” rating and set a $135.00 price target on shares of Kymera Therapeutics in a report on Thursday, August 6th. Mizuho upped their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Canaccord Genuity Group increased their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.70.

Insider Buying and Selling at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $79,321,592. The trade was a 6.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the transaction, the director owned 240,123 shares in the company, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,587,629 shares of company stock valued at $386,183,782. 15.98% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.